Deep Roots Chiropractic Health Center Offers Natural Pain Management in Bentonville
Tired of waking up feeling like your spine lost a fight with your mattress? You're not alone—and you're not out of luck. Deep Roots Chiropractic Health Center in Bentonville is helping locals say goodbye to chronic pain and hello to natural, drug-free relief.
Conveniently located at 103 SW Winsted Ln Suite 25, Deep Roots NWA is quickly becoming the go-to clinic for people who want real solutions—not just symptom patches. As a trusted back pain chiropractor in Bentonville, the team focuses on treating the root cause of pain so you can feel better—and stay that way.
'We don't hand out quick fixes,' said Dr. Ryan Carlson of Deep Roots Chiropractic Health Center. 'We help people reclaim their health with long-term solutions that actually work.'
Whether you're dealing with back, neck, or shoulder pain—or just feel like your body's been sending out distress signals—Deep Roots offers care that's customized, effective, and refreshingly honest. Their back and shoulder pain clinic approach blends gentle chiropractic adjustments with lifestyle support to help your body heal naturally.
What sets them apart?
From young professionals to busy parents to retirees, Bentonville residents are turning to Deep Roots for real results—and five-star care in a calm, welcoming space.
If your current routine includes painkillers, heating pads, and crossed fingers, it may be time to try something better.
To learn more or book your first visit, head over to www.deeprootsnwa.com.
Media Contact
Company Name: Deep Roots Health Center
Contact Person: Dr. Ryan Carlson
Email: Send Email
Phone: 479-334-0219
Address: 103 SW Winsted Ln #25
City: Bentonville
State: AR
Country: United States
Website: https://www.deeprootsnwa.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 hours ago
- CTV News
Trump administration is launching a new private health tracking system with Big Tech's help
WASHINGTON — The Trump administration is pushing an initiative for millions of Americans to upload personal health data and medical records on new apps and systems run by private tech companies, promising that will make it easier to access health records and monitor wellness. Leaders from more than 60 companies, including major tech companies such as Google and Amazon, as well as prominent hospital systems like the Cleveland Clinic, will convene at the White House on Wednesday afternoon to discuss what the administration is calling a 'digital health ecosystem.' The new system will focus on diabetes and weight management, conversational artificial intelligence that helps patients, and digital tools such as QR codes and apps that register patients for check-ins or track medications. The initiative, spearheaded by an administration that has already freely shared highly personal data about Americans in ways that have tested legal bounds, could put patients' desires for more convenience at their doctor's office on a collision course with their expectations that their medical information be kept private. 'There are enormous ethical and legal concerns,' said Lawrence Gostin, a Georgetown University law professor who specializes in public health. 'Patients across America should be very worried that their medical records are going to be used in ways that harm them and their families.' Officials at the Centers for Medicare and Medicaid Services, in charge of maintaining the system, have said patients will need to opt in for the sharing of their medical records and data, which will be kept secure. Officials say patients will benefit from a system that lets them quickly call up their own records without the hallmark difficulties, such as requiring the use of fax machines to share documents, that have prevented them from doing so in the past. 'We have the tools and information available now to empower patients to improve their outcomes and their healthcare experience,' Dr. Mehmet Oz, the administrator for CMS, said in a statement Wednesday. Once the system is set up, popular weight loss and fitness subscription service Noom, which has signed onto the initiative, will be able to pull medical records, including labs or tests, of its users into its AI-driven analysis of what might help users lose weight, CEO Geoff Cook told The Associated Press. 'Right now you have a lot of siloed data,' Cook said. Patients who travel across the country for treatment at the Cleveland Clinic often have a hard time obtaining all their medical records from various providers, said the hospital system's CEO, Tomislav Mihaljevic. He said the new system would eliminate that barrier, which sometimes delays treatment or prevents doctors from making an accurate diagnosis because they do not have a full view of a patient's medical history. Having seamless access to health app data, such as what patients are eating or how much they are exercising, will also help doctors manage obesity and other chronic diseases, Mihaljevic said. 'These apps give us insight about what's happening with the patient's health outside of the physician's office,' he said. CMS will also recommend a list of apps on that are designed to help people manage chronic diseases, as well as help them select health care providers and insurance plans. Digital privacy advocates are skeptical that patients will be able to count on their data being stored securely. The federal government has done little to regulate health apps or telehealth programs, said Jeffrey Chester at the Center for Digital Democracy. Health and Human Services Secretary Robert F. Kennedy Jr. and those within his circle have pushed for more technology in health care, advocating for wearable devices that monitor wellness and telehealth. Kennedy also sought to collect more data from Americans' medical records, which he has previously said he wants to use to study autism and vaccine safety. Kennedy has filled the agency with staffers who have a history of working at or running health technology startups and businesses. 'This scheme is an open door for the further use and monetization of sensitive and personal health information,' Chester said. Amanda Seitz, The Associated Press
CTV News
5 hours ago
- CTV News
‘Ozempic face' may be driving a cosmetic surgery boom
About two years ago, celebrity cosmetic dermatologist Dr. Paul Jarrod Frank noticed a new type of patient arriving at his New York practice. Amid an explosion in the number of Americans losing weight with drugs like Ozempic, he saw a 'dramatic spike' in clients experiencing unwelcome side effects. 'Although they felt much better losing weight, in some ways they felt they looked older,' he said via a voice note. 'And this was due to the loss of volume in their face.' Frank started using the term 'Ozempic face' — a label he believes he coined — to describe the phenomenon. It has since become a social media byword for the sagging skin and hollowed-out appearance that can accompany the use of GLP-1 medications like semaglutide (the active ingredient in branded drugs such as Ozempic and Wegovy). 'Usually, with people from their mid-40s and above, once you start losing 10-plus pounds, you can get this kind of deflated look,' said Frank, who is the founder of aesthetic health care brand PFRANKMD and the author of 'The Pro-Aging Playbook.' 'Certainly, people losing 20 or 30-plus pounds are going to have this problem.' Semaglutide works by stimulating the pancreas to trigger insulin production, curbing users' appetite and contributing to feelings of fullness. Although the U.S. Food and Drug Administration approved Ozempic to treat Type 2 diabetes, doctors now commonly prescribe it off-label for weight management. About 1 in 8 adults in the U.S. has used a GLP-1 drug, and of those, around 2 in 5 did so solely to lose weight, according to health policy non-profit KFF in 2024. Today, more than 20% of Frank's patients are using GLP-1s as part of what he called their 'longevity regimen.' The treatments sought after their weight loss include injectable dermal fillers to help restore facial volume, facelifts and fat transfers. 'You can only refill a deflated balloon so much, and often surgical intervention is necessary,' he said. But for many patients, he added, 'just upping the dosage of their volume replacement is more than enough. 'Someone who may have used one syringe of filler in the past is now using two or three.' 'It looked like I had melted' The American Society of Plastic Surgeons (ASPS), which publishes an annual report on surgery trends, recently found that 2 in 5 of its members' GLP-1 patients were considering undergoing cosmetic surgery — and 1 in 5 already had. Among the patients opting for a facelift was Kimberly Bongiorno, a local government land use administrator from Mount Arlington, New Jersey. Having lost weight after gastric sleeve surgery in 2019, she regained 40 pounds during the COVID-19 pandemic and was prescribed Wegovy last year. Despite describing the drug's impact as 'almost a miracle' — taking her weight from 170 to 125 pounds — the 55-year-old faced new concerns over her appearance. 'Everything just kind of hung and was very loose,' she said over Zoom, recalling seeing her face in a photo shared by a friend. 'I no longer felt like I had cheeks, and I had a lot of loose skin under my neck. 'It looked like I had melted. It was horrifying,' she added. 'It was so disheartening to see how my face looked and how it had changed, I thought I looked a lot older than I am.' After consulting plastic surgeon Dr. Anthony Berlet at his New Jersey office, Bongiorno underwent a deep plane facelift that lifted her skin and repositioned some of the deeper muscles and connective tissues. She also opted for a neck lift that refined and smoothed her neck contours while addressing excess skin left by her weight loss. 'Before I did this, I probably looked closer to 60, or maybe even older. And now I have people who I've recently met think I am in my 40s,' Bongiorno said, adding: 'People I haven't seen in a while say, 'You look so healthy and happy.' And that's nice to hear, because for a while, I didn't look healthy and certainly wasn't happy.' The number of facelifts performed in the U.S. jumped 8% between 2022 and 2023, according to ASPS data. The use of hyaluronic acid fillers has meanwhile doubled from 2.6 million Americans in 2017 — the year Ozempic was first cleared for diabetes — to over 5.2 million in 2023. The organization could not attribute these upticks exclusively to GLP-1 use, but its former president, Dr. Steven Williams, said the medications have had 'a global effect on aesthetic surgery.' 'Now we have a brand-new tool that actually has efficacy for so many patients,' said Williams, a board-certified plastic surgeon and founder of California's Tri Valley Plastic Surgery, over Zoom. He noted that GLP-1s come 'without substantial drawbacks' when compared with invasive procedures like gastric bypass surgery. 'We can now have an honest conversation with patients about a nonsurgical tool that's effective in weight loss,' he added. 'And as part of that conversation, there's an obligation to say, 'Look, this is really going to work, so you have to be prepared for what looking 20 or 50 pounds slimmer is going to be.'' The term 'Ozempic face' may speak to our times, but its symptoms — caused by a decrease in the subcutaneous fat that makes our faces plump — are nothing new. Cosmetic surgeons have long been treating the side effects of significant weight loss. In fact, one popular brand of dermal filler, Sculptra, was originally developed in the 1990s for HIV patients. As an adult, 'your body actually doesn't make more fat cells,' Williams said. 'As we lose or gain weight, those fat cells aren't multiplying or decreasing; they're getting bigger or smaller. And so as we lose weight, those fat cells now have decreased volume, and there's just less fullness.' Preventive measures Age can determine how patients' faces react to weight loss. People in their 20s and 30s, for instance, are far less likely to experience the appearance of aging due to GLP-1 use, Frank said. 'Because they have good skin elasticity, the skin rebounds much better,' he said. Patients aged 20 to 39 accounted for 14% of hyaluronic acid filler use in the U.S. and just 2% of facelift procedures last year, according to the ASPS. But both figures are on the rise. Gabriela Vasquez, 29, is among the younger patients using GLP-1 to undergo cosmetic procedures after rapid weight loss. An employee of one of Williams' Tri Valley Plastic Surgery clinics, she has dropped around 50 pounds since starting Ozempic in November. Although Vasquez is still working toward her target weight, she sought preventative Botox injections (more visible lines and wrinkles are, along with thinning lips, among the other side effects of GLP-1 use). She has also recently undergone microneedling, a procedure used to stimulate collagen production. 'One of my concerns was my jowls, because I felt I saw them when I was a little heavier,' she said over Zoom from the Bay Area. 'I think the microneedling definitely helped. 'I never had a jaw line,' she added. 'And a couple weeks ago, someone took a picture of me, and I had one, and I was like, 'Well, that's new.'' Vasquez did not rule out further cosmetic procedures as she continues losing weight — and not only to her face and neck. 'I'm seeing little things in my body that I'm like, 'Whoa, that would be nice to take care of,'' she said, referencing the appearance of excess skin under her arms. 'I could see myself — later down the line, once I get to my goal weight — doing something to kind of tighten everything up.' Frank, the cosmetic dermatologist, noted that 'Ozempic face' may be accompanied by a phenomenon he dubbed 'Ozempic body,' adding: 'One of the other major side effects of weight loss, particularly when it's done at a rate of more than one to two pounds a week, is muscle loss. And we see this all over the body.' The ASPS similarly notes the emerging term 'Ozempic makeover,' a suite of procedures that might also include tummy tucks, breast lifts and arm, thigh and buttock lifts. For instance, Bongiorno, the New Jersey facelift patient, has also undergone several other procedures with Dr. Berlet, including arm and thigh lifts, to address her excess skin. She estimates that after her upcoming breast lift, fat grafting and lower eyelid surgery, she will have spent about $80,000 on cosmetic procedures. 'Skin is heavy and uncomfortable,' she said. 'This wasn't something I did to go out there and be a supermodel. It was just to be comfortable, so I could get clothes on and not feel like I was dragging around all this extra weight.' Ongoing questions The long-term effect of GLP-1 medications on cosmetic medicine is yet to be fully understood. The assumption they might reduce demand for liposuction, for instance, has not come to bear: It remains the most common cosmetic surgical procedure in the US, growing in popularity by 1% last year, per ASPS data. What also remains to be seen is the effect that 'Ozempic rebound' — when patients regain weight after stopping the drugs — has on people who sought cosmetic procedures. A recent peer-reviewed study found that most people using the drugs for weight loss quit within a year. Data presented at this year's European Congress on Obesity meanwhile suggested that patients typically returned to their original weight within 10 months of stopping use, with University of Oxford researchers calling the findings a 'cautionary note' about using medication 'without a more comprehensive approach' to weight loss. For Williams, this further demonstrates why he and his plastic surgeon colleagues must take responsibility for their patients' 'entire journey,' not just their cosmetic procedures. 'We don't want these patients to be on these medications for a lifetime. We want it to be a temporary bridge to a healthier lifestyle,' he said, adding: 'It's our obligation to work harder with those patients, to talk about lifestyle changes, to get them plugged in to dietitians and to make sure that they're building muscle and exercising.' By Oscar Holland, CNN
National Post
7 hours ago
- National Post
Stallergenes Greer Announces Palforzia® Featured on "The Balancing Act" Airing on Lifetime TV
Article content National TV Segment Highlights FDA-Approved Oral Immunotherapy Treatment for Peanut Allergy Article content Segment premiered on Wednesday, July 30 and will be rebroadcast on Thursday, July 31, at 7:30 a.m. PT/ET Article content LENOIR, N.C. — Stallergenes Greer, a global leader in allergy therapeutics, today announced that a new segment of 'The Balancing Act ® ' airing on Lifetime TV featured its product Palforzia ® [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first and only U.S. Food and Drug Administration (FDA) approved oral immunotherapy treatment (OIT) for peanut allergy in children ages 1 through 17 years. 1 The Stallergenes Greer sponsored segment premiered nationwide on Wednesday, July 30 at 7:30 a.m. (ET/PT) and features the story of a family with a peanut allergic child who was treated with Palforzia ® . Article content 'We are proud to see Palforzia ® featured on 'The Balancing Act ®,' bringing national visibility to peanut allergy and a first of it's kind, FDA-approved oral immunotherapy treatment option for children and toddlers that can help to reduce the risk of life-threatening reactions that can occur with a peanut allergy,' Article content said Tibor Nemes, Executive Vice President, Head of Americas for Stallergenes Greer Article content . 'This segment is an opportunity to educate patients, caregivers and healthcare providers about Palforzia ®, and to further our commitment as Stallergenes Greer to provide innovative allergen immunotherapy (AIT) treatments to the allergy community that we serve.' Peanut allergy currently affects approximately 2% of the US pediatric population 2-3 Compared to other food allergies, peanut allergy is associated with higher rates of morbidity due to accidental exposure 4. The severity of reactions in some patients despite strict allergen avoidance efforts highlights the need for safe and effective therapies. 5 The featured segment included insights shared by Pediatric Allergist and Immunologist, Panida Sriaroon, M.D., on food allergies and the challenges that some patients with food allergies and their families may face. Dr. Sriaroon, also presented Palforzia ® and its significance as the first and only FDA-approved oral immunotherapy treatment option available in the treatment landscape for peanut allergy. Article content Palforzia ® was first approved by the FDA in 2020, under Aimmune Therapeutics, Inc., as an oral immunotherapy treatment (OIT) for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut in children ages 4 through 17 years. In 2024, the FDA approved Palforzia ® for the expanded indication for toddler patients (ages 1 through 3 years) and the toddler product was launched in March 2025 by Stallergenes Greer. Article content In addition to the July 30 premiere, the featured segment on 'The Balancing Act' will be rebroadcast on Thursday, July 31, at 7:30 a.m. (ET/PT). It can also be viewed on the show's website Palforzia ® is only available through a REMS (Risk Evaluation and Mitigation Strategy) program. Additional information about Palforzia ®, including Boxed Warning, full Prescribing Information and Medication Guide is available at *The participants featured in this segment were compensated for their time. Article content ABOUT PALFORZIA ® Article content Palforzia ® is an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. Palforzia ® is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial Dose Escalation may be administered to patients aged 1 to 17 years. Up-Dosing and Maintenance may be continued in patients 1 year of age and older. Article content Palforzia ® is to be used in conjunction with a peanut-avoidant diet. Article content Limitation of Use: Not indicated for the emergency treatment of allergic reactions, including anaphylaxis. Article content Palforzia ® is approved by the U.S. Food and Drug Administration (FDA) for ages 1 through 17 years. Article content WARNING: ANAPHYLAXIS: Palforzia ® can cause anaphylaxis, which may be life-threatening and can occur at any time during Palforzia ® therapy. Prescribe epinephrine, instruct and treat patients on its appropriate use, and instruct patients to see immediate medical care upon its use. Do not administer Palforzia ® to patients with uncontrolled asthma. Dose modifications may be necessary following a anaphylactic reaction. Observe patients during and after administration of the Initial Dose Escalation and the first dose of each Up-Dose level, for at least 60 minutes. Palforzia ® is available only through a restricted program called the Palforzia ® REMS. Article content is contraindicated in patients with uncontrolled asthma, or with a history of eosinophilic esophagitis and other eosinophilic gastrointestinal diseases. Article content WARNINGS AND PRECAUTIONS: Anaphylaxis: Article content Palforzia Article content ® Article content can cause anaphylaxis, which may be life-threatening. Palforzia Article content ® Article content is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Palforzia Article content ® Article content REMS because of the risk of anaphylaxis. Only prescribers, healthcare settings, pharmacies, and patients certified and enrolled in the REMS Program can prescribe, receive, dispense or administer Palforzia Article content ® Article content ® Article content dosing, including Maintenance and in subjects who have undergone recommended Up-Dosing and dose modification procedures. Do not initiate Palforzia Article content ® Article content treatment in a patient who has had severe or life-threatening anaphylaxis within the previous 60 days. Palforzia Article content ® Article content may not be suitable for patients with certain medical conditions that may reduce the ability to survive anaphylaxis, including, but not limited to, markedly compromised lung function, severe mast cell disorder, or cardiovascular disease. In addition, Palforzia Article content ® Article content may not be suitable for patients taking medications that can inhibit or potentiate the effects of epinephrine. All Initial Dose Escalation doses and the first dose of each Up-Dosing level must be administered under observation in a certified healthcare setting. Patients may be more likely to experience allergic reactions following Palforzia Article content ® Article content administration in the presence of cofactors such as exercise, hot water exposure, intercurrent illness (e.g., viral infection), or fasting. Other potential cofactors may include menstruation, sleep deprivation, nonsteroidal anti-inflammatory drug use, or uncontrolled asthma. Patients should be proactively counseled about the potential for the increased risk of anaphylaxis in the presence of these cofactors. If possible, adjust the time of dosing to avoid these cofactors. If it is not possible to avoid these cofactors, consider withholding Palforzia Article content ® Article content temporarily. Article content Asthma: Article content ® Article content . Palforzia Article content ® Article content should be temporarily withheld if the patient is experiencing an acute asthma exacerbation. Following resolution of the exacerbation, resumption of Palforzia Article content ® Article content ® Article content . Article content Eosinophilic Gastrointestinal Disease: Article content Discontinue Palforzia Article content ® Article content and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent gastrointestinal symptoms, including dysphagia, vomiting, nausea, gastroesophageal reflux, chest pain, or abdominal pain. Article content Gastrointestinal Adverse Reactions: Article content ® Article content -treated subjects, and dose modification should be considered for patients who report these reactions. For severe or persistent gastrointestinal symptoms, consider a diagnosis of eosinophilic esophagitis. Article content ® Article content Article content (incidence ≥5%) are cough, sneezing, rhinitis, nasal congestion, throat irritation, wheezing, abdominal pain, vomiting, diarrhea, oral pruritus, oropharyngeal pain, urticaria, rash, pruritus, and perioral dermatitis. The most common adverse reactions reported in subjects ages 4 through 17 years treated with Palforzia Article content ® Article content (incidence ≥5% and at least 5% greater than placebo) are abdominal pain, vomiting, nausea, oral pruritus, oral paresthesia, throat irritation, cough, rhinorrhea, sneezing, throat tightness, wheezing, dyspnea, urticaria, anaphylactic reaction, and ear pruritus. Article content ABOUT THE BALANCING ACT Article content The Balancing Act ® is a morning show created and produced by BrandStar that offers sensible solutions and essential information in a fun, entertaining format; providing resources to help people do life better. The Balancing Act features everything from delicious recipes, style makeovers and dream getaways to parenting tips and the latest news in health and wealth. Tune in to The Balancing Act weekdays at 7:30 a.m. (ET/PT) on Lifetime ® and find all previously aired episodes on ABOUT STALLERGENES GREER Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. Article content PALFORZIA [package insert]. Lenoir, NC; Greer Laboratories, Inc. Article content 2 Article content Bilaver LA, Chadha AS, Doshi P, O'Dwyer L, Gupta RS. Economic burden of food allergy: A systematic review. Ann Allergy Asthma Immunol 2019;122:373–80 e1. Article content 3 Article content Gupta RS, Springston EE, Warrier MR, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics 2011;128:e9–17. Article content 4 Article content The global burden of illness of peanut allergy: A comprehensive literature review. Jay A. Lieberman, Ruchi S Gupta, Rebecca C. Knibb, Tmirah Haselkorn, Stephen Tilles, Douglas P. Mack, and Guillaume Pouessel. Online: Article content . Accessed August 31, 2023 Article content Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-3. Accessed August 31, 2023. Article content Article content Article content Article content Article content Contacts Article content Stallergenes Greer USA Article content Article content Article content
